Biodexa Pharmaceuticals Partners with Syngene International to Manufacture MTX240 Active Pharmaceutical Ingredient.

jueves, 2 de abril de 2026, 11:51 am ET1 min de lectura
BDRX--

Biodexa Pharmaceuticals shares surged 69% after announcing a partnership with Syngene International for the manufacture of MTX240 active pharmaceutical ingredient and dosage form. The stock is currently trading at $1.05 on the Nasdaq, up 69.49% from its opening price of $0.9235. The company plans to file an IND and initiate a Phase 1b/2a study by the end of the year.

Biodexa Pharmaceuticals Partners with Syngene International to Manufacture MTX240 Active Pharmaceutical Ingredient.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios